Editorial
A New Era in the Treatment of Scleroderma-associated Interstitial Lung Disease?
D. Launay .......................................................... 1619

Articles
Predictive Value of Arterial Stiffness and Subclinical Carotid Atherosclerosis for Cardiovascular Disease in Patients with RA

ACR/EULAR Definitions of Remission Are Associated with Lower Residual Inflammatory Activity Compared with DAS28 Remission on Hand MRI in RA
M.P. Lisbona, A. Solano, J. Ares, M. Almirall, T.C. Salman-Monte, J. Maymó ........................................ 1631

Toreforant, A Histamine H4 Receptor Antagonist, in Patients with Active RA Despite MTX Therapy: Results of 2 Phase II Studies

Effect of Adherence to Protocolized Targeted Intensifications of Disease-modifying Antirheumatic Drugs on Treatment Outcomes in RA: Results from an Australian Early Arthritis Cohort
N.T. Wabe, M.J. Sorich, M.D. Wechalekar, et al .................................. 1643

Infection in Southern Chinese Patients with SLE: Spectrum, Drug Resistance, Outcomes, and Risk Factors
D. Chen, J. Xie, H. Chen, et al .......................................................... 1650

Associations of the Levels of C4d-bearing Reticulocytes and High-avidity Anti-dsDNA Antibodies with Disease Activity in SLE
C. Mora, J. Medina-Rosas, A.M. Santos, et al .................................. 1657

The Recurrence of Digital Ulcers in Patients with SSC after Discontinuation of Oral Treprostinil
A.A. Shah, E. Schiopu, S. Chatterjee, et al .......................... 1665

An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial
D. Khanna, C. Albera, A. Fischer, et al .................................. 1672

Contents continued on page xii
Pediatric Rheumatology

The Systemic JIA Cohort of the Childhood Arthritis and Rheumatology Research Alliance Registry: 2010–2013
G. Janow, L.E. Schanberg, S. Setoguchi, et al, and the CARRA Legacy Registry Investigators. 1755

Images in Rheumatology

Unilateral Macular Lymphocytic Arteritis
A. Arana-Guajardo, C. Mendoza-Rodríguez, I. Miranda-Maldonado 1763

Correspondence

Defining Low Disease Activity States in PsA Using Novel Composite Disease Instruments
E. Lubrano, F.M. Perrotta 1765

Reply L.C. Coates, P.S. Helliwell 1766

Mycophenolate Mofetil in Refractory Cutaneous Lupus Erythematosus: No Definitive Evidence
C. Bachmeyer, S. Galmiche, A. Fayand, A. Degachi, S. Georgin-Lavialle 1766


Letters

Four Cases of Anti-PM/ScI Antibody-positive JuvenileOverlap Syndrome with Features of Myositis and SSc
L. Fotis, K.W. Baszis, A.J. White, A.R. French 1768

Development of Nephrotic Syndrome in a Patient with RA Treated with Certolizumab
R.R. Butendieck Jr., T. Bhattacharya, X. Geiger 1770

Correction

Predictors of Loss of Remission and Disease Flares in Patients with Axial Spondyloarthritis Receiving Antitumor Necrosis Factor Treatment: A Retrospective Study
E. Lubrano, F.M. Perrotta, M. Manara, et al 1772

Meetings in Rheumatology